Related by context. All words. (Click for frequent words.) 76 Abstract Number 71 Poster Session 68 Oral Presentation 68 Poster Discussion 66 Poster Presentation 64 J Clin Oncol 64 Antiviral Therapy 62 Late Breaker 62 Pharmacokinetics 62 abstr 61 Oral Session 61 Safety Tolerability 61 SABCS 61 AACR NCI EORTC 60 FASEB J. 60 Suppl. 60 Developmental Therapeutics Immunotherapy 60 Antiviral Activity 60 Kinase Inhibitor 59 Poster Presentation # 59 Relapsing Multiple Sclerosis 59 J Am Soc 59 Nephrol 59 Cancer Res 59 Suppl 59 Vitro Activity 59 Selective Cardiac Myosin 59 Oral Fingolimod 58 J Natl Cancer Inst 58 Gastrointestinal Cancers Symposium 58 SA FC# 58 HDAC Inhibitor 58 J Biol Chem 58 histone deacetylase HDAC inhibitor 58 Randomized Double Blind Placebo 57 Am J Physiol 57 EORTC NCI AACR 57 #nd EORTC NCI 57 Dendritic Cells 57 Randomized Double blind 57 Chronic Lymphocytic Leukemia 57 Molecular Targets 57 Ann Intern Med 57 #:#-# [023] 57 Antigen Specific 57 Mantle Cell Lymphoma 57 EORTC 56 Pharmacodynamic 56 Bortezomib 56 Am J Epidemiol 56 Kidney Int 56 Ann Oncol 56 fosbretabulin 56 Environ Health Perspect 56 Orally Active 56 Chronic Hepatitis C 56 Randomized Phase 56 Nat Genet 56 EGFR HER2 56 Fast Skeletal Troponin 56 EpCAM 56 J Rheumatol 56 Prospective Randomized Trial 56 Clinical Oncology Annual Meeting 56 AACR #st Annual Meeting 56 nd Annual Meeting 56 Preclinical Study 56 Nat Rev 56 J Clin Endocrinol Metab 56 Chicago Multidisciplinary Symposium 56 Thromb Haemost 56 J Clin 56 Eur Respir J 56 antitumor activity 56 Cell Lymphoma 56 Clinical Trial Results 55 Br J Psychiatry 55 Solid Tumors 55 Oral Abstract 55 Controlled Trial 55 Arch Neurol 55 ICAAC 55 Nat Med 55 II Clinical Trial 55 CROI 55 EMBO J. 55 Am J Pathol 55 Cytochrome P# 55 suppl 55 J Clin Invest 55 Dose Escalation Study 55 EORTC NCI AACR Symposium 55 Arch Intern Med 55 Melanoma Skin Cancers 55 #:#-# [031] 55 metastatic renal cell carcinoma 55 Double Blind Placebo 55 Decitabine 55 Eur J Endocrinol 55 Pharmacodynamics 55 Genotypes 55 ASCO Annual Meeting 55 Antitumor Activity 55 S# S# [001] 55 Study Evaluating 55 Initiated Phase 55 Obstet Gynecol 55 entitled Synergistic 55 Neurol 55 Abstract Free Full Text 55 prostate cancer mCRPC 55 Immunogenicity 55 #th Annual Interscience 55 Am J Cardiol 55 Pharmacokinetics PK 54 J Psychopharmacol 54 HCV Genotype 54 Androgen Receptor 54 compound AEZS 54 Ann Rheum Dis 54 Receptor Antagonist 54 polycythemia vera PV 54 Hsp# Inhibitor 54 Pharmacokinetic 54 Br J Cancer 54 Hematology ASH Annual Meeting 54 Tolerability 54 J Clin Psychiatry 54 Controlled Study 54 AASLD 54 Placebo Controlled Study 54 selective kinase inhibitor 54 Proc Am Soc 54 Castration Resistant Prostate Cancer 54 ASCO GU 54 pan HDAC inhibitor 54 dose escalation trial 54 colon carcinoma 54 Placebo Controlled Trial 54 Sipuleucel T 54 Nucleic Acids Res 54 Mol Cell 54 induces apoptosis 54 Oncol 54 Polymerase Inhibitor 54 J Nutr 54 Cytotoxicity 54 Polymorphism 54 Gynecol Oncol 54 Randomized Phase III 54 Multimeric 54 Liposomal 54 Phase 2b Study 54 Br J Dermatol 54 Anti Tumor 54 ASCO GI 54 Multiple Myeloma MM 54 doi #.#/fj.#-# 54 Hemodialysis Patients 54 Pharmacokinetic PK 54 Nephrol Dial Transplant 54 Multiple Myeloma 54 Proc Natl Acad Sci 54 Diffuse Large B 53 Dose Escalation 53 Arch Surg 53 Selective Cardiac Myosin Activator 53 Hematology Annual Meeting 53 #:#-# [028] 53 Abstract Full Text 53 Denufosol 53 Crit Care Med 53 Enzastaurin 53 Eur Urol 53 AACR San Antonio 53 Prospective Multicenter 53 ASCO abstract 53 Tumor Progression 53 Genitourinary Cancers Symposium 53 preclinical efficacy 53 R roscovitine 53 Pharmacological 53 Oritavancin 53 FASEB J 53 Obes Res 53 Novel Inhibitor 53 pharmacokinetics PK 53 xenograft models 53 Genome Res 53 NSABP B 53 huN# DM1 53 Progenitor Cells 53 Biol 53 Kahalalide F 53 Clin Infect Dis 53 Dermatol 53 Relapsed Refractory 53 ON #.Na 53 Free Full Text 53 #th Interscience Conference 53 peripheral blood mononuclear 53 Metastatic Melanoma 53 Meta Analysis 53 Pharmacokinetic Study 53 ongoing Phase 1b 53 #S #S [003] 53 Kinase Inhibitors 53 Tumor Biology 53 Endocrinol Metab 53 BIBW 53 depsipeptide 53 J Affect Disord 53 Curr Opin 53 transthyretin TTR mediated amyloidosis 53 histone deacetylase inhibitor 53 Peginterferon 53 #:#-# [020] 53 HCV SPRINT 52 Hematological Malignancies 52 Room #AB [002] 52 Dose Response 52 Regul Integr Comp Physiol 52 MGd 52 pharmacokinetic PK 52 Anticancer Drugs 52 Biol Psychiatry 52 INGN 52 BiTE antibody MT# 52 Pooled Analysis 52 th Interscience Conference 52 Scientific Sessions 52 J Child Adolesc 52 MT# MEDI 52 Anti Tumor Activity 52 Mol Cell Biol 52 Int J Cancer 52 ovarian carcinoma 52 Cutaneous T 52 Prostate Cancer Symposium 52 EASL 52 ERA EDTA 52 Supplemental Figure 52 Advanced Renal Cell 52 TMC# C# 52 Podium Presentation 52 Child Adolesc Psychiatry 52 tumor xenograft models 52 ASH Annual Meeting 52 Efficacy 52 Orthop Surg 52 Clinical Oncology ASCO Annual 52 #S #S [002] 52 sunitinib Sutent ® 52 AACR symposium 52 Clinical Outcome 52 PMID # [002] 52 Initiate Phase 52 suppl. 52 Parathyroid Hormone 52 Arch Gen Psychiatry 52 Am J Gastroenterol 52 Endocrinol 52 Randomized Phase II 52 Crit Care 52 Inhibits 52 ABCSG 52 AUA Annual Meeting 52 J Neurol Neurosurg Psychiatry 52 Phase Ib Clinical Trial 52 AASLD Meeting 52 lexidronam injection 52 RNAi Therapeutic 52 Ophthalmol 52 Phase Ib clinical 52 Hepatocellular Carcinoma 52 Nat Neurosci 52 Breaking Clinical Trials 52 Potent Antiviral Activity 52 REG2 52 Phase IIa Clinical Trial 52 Blinatumomab 52 davunetide intranasal AL 52 Targeted Therapy 52 ExTRACT TIMI 52 Prognostic Significance 52 Arthritis Rheum 52 Adefovir 52 Rheumatol 52 Clin Oncol 52 Protease Inhibitor 52 J Am Acad 52 Renal Physiol 52 Preclinical Data 52 BCIRG 52 Unresectable 52 B Cell Lymphoma 52 #:#-# [022] 52 Psychol Med 52 N Engl J 51 Prolongs Survival 51 Respir Med 51 Phenotype 51 leukemia AML 51 Hematol 51 Soc Sci Med 51 Heart Circ Physiol 51 non nucleoside inhibitor 51 Chronic Lymphocytic Leukemia CLL 51 Novel Oral 51 CLL SLL 51 papillary renal cell carcinoma 51 satraplatin Phase 51 Bladder Cancer 51 Clin Pharmacol Ther 51 Phase Ib study 51 Drug Candidate 51 dose escalation clinical 51 Int J Epidemiol 51 #:#-# [029] 51 Therapeutic Targets 51 Immune Responses 51 Antitumor 51 Antimicrobial Agents 51 Psychopharmacol Bull 51 Oncogene 51 Multicenter Study 51 Nutr 51 Carfilzomib 51 Clin Chem 51 Pediatr 51 Renal Cell Carcinoma 51 pharmacodynamic PD 51 Double Blind Randomized 51 Nat Biotechnol 51 leukemia CLL 51 Tumor Angiogenesis 51 Proteasome 51 SCH # 51 Ann Surg 51 Presents Preclinical Data 51 Int Clin Psychopharmacol 51 targeting CD# 51 Phase 2a Clinical Trial 51 J Virol 51 Autoimmune Diseases 51 Relapsed 51 AACR IASLC Joint 51 Clinical Trials Update 51 Randomized Double Blind 51 Br J Haematol 51 Ann Emerg Med 51 #:#-# [035] 51 nab paclitaxel 51 Phase Ib II 51 J Pediatr 51 hypoxia inducible factor 51 Eur J Cancer 51 poly ADP ribose polymerase 51 Demonstrates Potent 51 Systemic Sclerosis 51 Randomized Study 51 ECCMID 51 Genitourinary Cancer 51 familial amyloidotic polyneuropathy FAP 51 Randomized Controlled 51 PEG IFN 51 ORAL Sync 51 Cell Physiol 51 Syndr 51 Preclinical Models 51 Postmenopausal Women 51 Antiangiogenic 51 Immunomodulatory 51 Cachexia 51 Clinical Antipsychotic Trials 51 Cardiol 51 Biological Therapy 51 J Neurosci 51 EVEREST II 51 Nat Clin Pract 51 Psychiatry Clin Neurosci 51 CrossRef Medline 51 Upregulation 51 urothelial carcinoma 51 Treating Chronic 51 phase Ib 51 vascular disrupting agent 51 TG MV 51 anti leukemic 51 #:#-# [002] 51 Society CTOS 51 Toxicities 51 MEK inhibitor 51 multicenter phase 51 Poster Presentations 51 #nd Annual Meeting 51 Am J Clin 51 Newly Diagnosed Multiple Myeloma 51 Placebo Controlled 51 Protein Kinase 51 Immunol 51 5 Fluorouracil 51 J Urol 51 Article ChemPort 51 PNP inhibitor 51 J Allergy Clin 51 ENMD # 51 Stent Thrombosis 51 Gastrointest Liver Physiol 51 AACR #nd Annual Meeting 51 Autoimmunity 51 J Med 50 cell lymphoma CTCL 50 sunitinib Sutent 50 RECORD1 50 GSK # 50 LUX Lung 50 Potent Inhibitor 50 Clinical Efficacy 50 Capecitabine 50 Arch Dermatol 50 selective inhibition 50 Eur J Neurol 50 Cell Mol Physiol 50 ADA Scientific Sessions 50 J Infect Dis 50 Acute Ischemic Stroke 50 e# [001] 50 HER2 positive metastatic breast 50 AACR Symposium 50 Chemotherapy ICAAC 50 Oral Presentations 50 Pathol 50 SWOG 50 Aflibercept 50 Cancer Cachexia 50 Gastric Cancer 50 plasma pharmacokinetics 50 Psychol 50 Acta Psychiatr Scand 50 Epratuzumab 50 erlotinib Tarceva ® 50 NASDAQ CYTK announced 50 Abstract P# [002] 50 PKC# 50 Aliskiren 50 Universal Flu Vaccine 50 Plus Ribavirin 50 Lancet Oncol 50 Breast Cancer Symposium 50 Glufosfamide 50 XL# SAR# 50 L# L# [001] 50 CALGB 50 ORMD 50 PRTX 50 Eur Heart 50 HGS ETR2 50 Mol Biol 50 J Exp Med 50 Neurosci 50 gemcitabine carboplatin 50 recurrent glioblastoma multiforme 50 Traficet EN 50 Bosentan 50 Receptor Agonist 50 Previously Treated 50 Article PubMed ChemPort 50 oral prodrug 50 PXD# 50 Kidney Transplant Recipients 50 Gastrointestinal Cancer 50 Diabet Med 50 Neoplasia 50 Adjuvant Chemotherapy 50 Eur Arch 50 dasatinib Sprycel ® 50 imatinib Gleevec ® 50 Cell Mol Biol 50 Intervention Effectiveness 50 metastatic malignant 50 Hodgkin lymphoma HL 50 Metastatic Prostate Cancer 50 Room #B 50 TAXUS ATLAS 50 J Consult Clin 50 novel histone deacetylase 50 Anesth Analg 50 Safinamide 50 CTRC AACR San Antonio 50 Biologic Therapy 50 pharmacodynamic 50 Myelodysplastic Syndromes 50 Drug Discov 50 registrational Phase 50 J Clin Epidemiol 50 evaluating tivozanib 50 Chronic Myeloid Leukemia 50 J Clin Psychopharmacol 50 mg TID 50 Phase Ib clinical trials 50 GRNCM1 50 Aplidin R 50 Nucleoside 50 J Psychiatry 50 AACR Meeting 50 SCCHN 50 J Am Coll 50 s# s# 50 breast carcinoma 50 Multicenter Phase 50 multicentre randomized 50 Tumor Response 50 Preclinical 50 HCV NS5B polymerase 50 Cancers Symposium 50 Cell Adhesion 50 Joint Surg Am 50 E CENP E 50 J Physiol 50 Peginterferon Alfa 2a 50 Meets Primary Endpoint 50 AEZS 50 multiple myeloma MM 50 Anti CD# Antibody 50 Cloretazine ® 50 INCB# [001] 50 Annual Scientific Sessions 50 NMIBC 50 Annual ICAAC 50 Dose Ranging Study 49 Endocrine Society #st 49 pancreatic adenocarcinoma 49 Mol Psychiatry 49 gefitinib Iressa 49 J Nerv Ment Dis 49 Refractory Hodgkin Lymphoma 49 Hematology 49 HIF PHI 49 Comparative Physiology 49 Molecular Therapeutics 49 Infect Dis 49 Clinical Virology 49 #-# Full Text 49 #:#-# [033] 49 Patients Treated With 49 Randomized phase 49 PI3K/mTOR 49 Investigational Drug 49 tumors GIST 49 Arch Pediatr Adolesc Med 49 Inflammatory Pain 49 receptor tyrosine kinase inhibitor 49 melphalan prednisone 49 Hormone Refractory Prostate Cancer 49 ICAAC IDSA 49 ASCO Gastrointestinal Cancers Symposium 49 Systemic Delivery 49 NSCLC 49 Int J Radiat Oncol 49 cell lymphoma ALCL 49 Phase IIA 49 Monotherapy 49 targeted antifolate 49 Intervention Trial 49 Mammalian Cells 49 Microbiol 49 enzastaurin 49 Aust Psychiatry 49 AHA Scientific Sessions 49 Sym# 49 Urol 49 PSN# [002] 49 • dcastell@visalia.gannett.com • 49 Doxil ® 49 Hematology Meeting 49 Angiogenesis 49 #mg BID [003] 49 bleomycin 49 cisplatin resistant 49 Article PubMed ISI ChemPort 49 randomized discontinuation trial 49 Eur J 49 suppl #S 49 Anticancer Drug 49 Myelofibrosis 49 Phys Ther 49 tolerability pharmacokinetics 49 Endovascular Valve Edge 49 Psychopharmacol 49 Phase 2b Clinical Trial 49 Systemic Lupus Erythematosus 49 JAK2 Inhibitor 49 #:# -# [005] 49 Am J Respir 49 Neurosurg 49 ECCO ESMO 49 viral kinetics 49 APOPTONE 49 liposomal doxorubicin 49 H# H# [003] 49 Follicular Lymphoma 49 resolvin 49 Cochrane Database Syst Rev. 49 Immunosuppression 49 Digestive Disease Week 49 Randomized Controlled Trial 49 Med Assoc 49 Glioma 49 Toxicol 49 PSMA ADC 49 PMID # [001] 49 Physiol 49 lymphoid malignancies 49 localized renal 49 Clin Endocrinol 49 Attenuates 49 #:#-# [037] 49 FOLFOX6 49 J Psychiatr Res 49 OXi# 49 Preclinical Efficacy 49 See CLINICAL PHARMACOLOGY 49 Guanilib 49 J Neurosurg 49 ASCO Breast Cancer 49 CCX# 49 Adjuvant Therapy 49 galiximab 49 Tanespimycin 49 Carcinoma 49 stage IIIB 49 Scientific Session 49 Ranolazine 49 Clinical Oncology 49 Well Tolerated 49 essential thrombocythemia ET 49 Leukemias 49 Seliciclib 49 advanced hepatocellular carcinoma 49 Miner Res 49 leukemia CML 49 ARRY # 49 sorafenib Nexavar 49 CEQ# 49 TRANSFORMS 49 Biol Phys 49 breast carcinomas 49 BiTE ® 49 verteporfin 49 cetuximab Erbitux R 49 Malignant Melanoma 49 st Annual Meeting 49 posaconazole 49 AACR Annual Meeting 49 Oligonucleotides 49 metastatic castration resistant 49 Perifosine 49 CYT# potent vascular disrupting 49 Risk Stratification 49 Metastatic Renal Cell Carcinoma 49 Septic Shock 49 #:# -# [004] 49 ANN INTERN MED 49 RCW Breast Cancer 49 EURIDIS 49 AAG geldanamycin analog 49 Phase III ALLEGRO 49 Dent Res 49 Cell Transplant 49 proteasome inhibitor 49 #st Annual Meeting 49 Int J 49 Inflammatory Arthritis 48 EORTC NCI 48 Vaccine Adjuvant 48 prostate cancer HRPC 48 ESMO 48 Symposium SABCS 48 Nilotinib 48 AEG# 48 Mil Med 48 Anesth 48 Multicenter 48 PubMed ISI ChemPort 48 NSABP 48 doi #.# 48 INCB# [003] 48 Liver Diseases 48 #:#-# [016] 48 Article PubMed 48 S1 S# [002] 48 HGS ETR1 48 Romidepsin 48 Fulvestrant 48 Pegylated Liposomal Doxorubicin 48 Hematology ASH 48 XL# XL# XL# 48 Solorel TM 48 Edge STudy 48 Intracranial Aneurysms 48 #:#-# [006] 48 CALGB # [002] 48 Gynecol 48 ligand TRAIL 48 NCIC CTG 48 farletuzumab 48 perifosine KRX 48 TASKi2 48 Presents Preclinical 48 Patients Treated 48 #:#-# [025] 48 Phase 2a clinical 48 Cell Biol 48 neratinib 48 #rd Annual CTRC 48 Interferon Alfa 48 Cardiotoxicity 48 pharmacokinetic profile 48 Virologic 48 Am J Obstet 48 Severe Sepsis 48 Preclinical Studies 48 ENESTnd 48 Sustained Efficacy 48 Myocardial Infarction Study 48 Mayo Clinic Rochester MN 48 Treatment Outcome 48 multicenter Phase 48 Initiates Phase 48 BIOCOM Investor Conference 48 solid tumors 48 postmenopausal osteoporotic women 48 Rehabil 48 Systematic Review 48 mRCC 48 RGB # 48 Anticancer Activity 48 GRN#L 48 pharmacokinetic PK study 48 pertuzumab 48 TRO# 48 safety tolerability pharmacokinetic 48 PO# [003] 48 NEUVENGE 48 Cell Lung Cancer 48 Psychiatry Res 48 ASCO 48 novel VDA molecule 48 alvespimycin 48 antibody MT# 48 Clinical Microbiology 48 hepatocellular carcinoma 48 imatinib resistant 48 Glioblastoma Multiforme 48 myelofibrosis MF 48 plus prednisone 48 refractory acute myeloid 48 lymphoid cells 48 Lenalidomide 48 Crit Rev 48 Cancer Incidence Mortality 48 CTAP# Capsules 48 ErbB2 positive 48 J Thorac Cardiovasc Surg 48 Hepatocellular 48 Schizophr Bull 48 Protease Inhibitors 48 :# [003] 48 Sports Exerc 48 RECIST Response Evaluation Criteria 48 Therapeutics TCT scientific 48 Ozarelix 48 Genetic Variation 48 Oral Mucositis 48 League Against Rheumatism 48 Diabetologia 48 multicenter Phase II 48 Carcinogenesis 48 Psychiatr 48 Malignant Lymphoma 48 I# I# [002] 48 fallopian tube carcinoma 48 T2DM 48 #:# -# [006] 48 Biochem Pharmacol 48 relapsed refractory multiple myeloma 48 chemoresistance 48 Cutaneous Melanoma 48 Medical Oncology ESMO 48 Amrubicin 48 Int J Geriatr Psychiatry 48 #:#-# [018] 48 Multicenter Randomized 48 ALN TTR 48 Onc 48 Randomised 48 Bosutinib 48 Genes Dev 48 pomalidomide 48 ENMD 48 Biotechnol 48 imetelstat 48 Cyclophosphamide 48 Oral Presentation # 48 San Antonio Breast Cancer 48 Annu Rev 48 myelofibrosis polycythemia vera 48 Adjuvant Treatment 48 PEGylated interferon beta 1a 48 Presents Positive 48 radiation sensitizer 48 Clin Orthop 48 DOI #.#/j.cell.#.#.# 48 Myelodysplastic Syndrome 48 darinaparsin ZIO 48 FOLFIRI 48 refractory multiple myeloma 48 vivo efficacy 48 ISTODAX ® 48 IND Application 48 CUDC 48 Neuroendocrine 48 Retrovirus 48 EULAR 48 Phase Ib 48 abacavir lamivudine 48 Phase 1b trial 48 DOI #.#/S#-# 48 ASH Abstract # 48 AACR 48 Schizophr Res 48 Long Term Efficacy 48 pheochromocytoma 48 Clinical Trial Evaluating 48 J Fam Pract 48 Phase 2b Trial 48 Proc Am 48 Natalizumab 48 NCCTG N# 48 GASTRO 48 Fludarabine 48 gastrointestinal stromal tumor GIST 48 trabectedin 48 PROSTASCINT R 48 ZFP Therapeutic 48 BAL# [002] 48 fluoropyrimidine 48 gemcitabine Gemzar ® 48 Adenoma Prevention 48 Hematologic 48 Cell Non Hodgkin 48 Liver Transplantation 48 J Immunol 48 EGFr 48 recombinant tissue plasminogen 48 dasatinib Sprycel 48 Sirolimus Eluting Stent 48 SU# [003] 48 orally administered inhibitor 48 Omacetaxine 48 mitomycin 48 panobinostat 47 Present Preclinical Data 47 J Acquir Immune Defic 47 castration resistant prostate cancer 47 refractory chronic lymphocytic 47 Sails Pavilion 47 epithelial tumors 47 Hedgehog Pathway Inhibitor 47 vinca alkaloid 47 CLL8 47 Kidney Function 47 bendamustine 47 ISPOR 47 CCX# B 47 Room #A 47 sipuleucel T 47 PEGylated Fab fragment 47 Metastatic Colorectal Cancer 47 Movement Disorder 47 mg BID 47 cell acute lymphoblastic 47 Developmental Therapeutics 47 Induces 47 Chemotherapeutic Agents 47 Subgroup Analysis 47 Androxal TM 47 Eluting Stent 47 Renal Function 47 Phase IIb Trial 47 ChemPort 47 Small Molecule 47 Clinical Oncology ASCO 47 TO AVOID PREGNANCY WHILE 47 Metastatic 47 HuMax CD4 47 myeloproliferative diseases 47 hepatocellular carcinoma HCC 47 Intracellular 47 Pralatrexate 47 administered subcutaneously 47 Hematological 47 Epithelium 47 orally inhaled migraine 47 Prospective Randomized 47 Oxidative Stress 47 Psychiatr Serv 47 Pharmacokinetic Pharmacodynamic 47 resistant ovarian cancer 47 Combination REOLYSIN R 47 BRIM3 47 #:# -# [001] 47 mCRC patients 47 tanespimycin 47 Phase IIb Clinical Trial 47 Human Molecular Genetics 47 recurrent malignant glioma 47 IL# PE#QQR 47 Outpatient Setting 47 J Gerontol 47 Recombinant Human 47 #:#-# [014] 47 Heart Failure Patients 47 AACR NCI EORTC Molecular 47 Beta catenin pathway 47 Patients Receiving 47 BRIM2 47 doi #.#/S#-# 47 paclitaxel cisplatin 47 Schizophrenia Bulletin 47 RTOG 47 ganetespib 47 Cerebral Cortex 47 Acute Myeloid Leukemia 47 Diabetic Neuropathy 47 antiviral activity 47 CD# + [002] 47 Humanized Anti 47 ENDO 47 lung carcinomas 47 #:#-# [030] 47 BJU Int 47 Randomized 47 J Appl Physiol 47 Philadelphia Chromosome Positive 47 Mol Med 47 HNSCC 47 Thoracic Oncology 47 taxane resistant 47 Novel Mechanism 47 Article ISI ChemPort 47 Aggressive Reduction 47 Interferon alfa 47 Acta Paediatr 47 Canaccord Adams Hepatitis C 47 Br J Clin Pharmacol 47 assessing T DM1 47 pharmacodynamic effects 47 J Invest Dermatol 47 recurrent glioma 47 Immunotherapeutic 47 HDACi 47 Varespladib 47 Clinical Evaluation 47 Lubiprostone 47 Left Ventricular 47 Supplementary Appendix 47 Cancer Epidemiol Biomarkers Prev 47 prostate cancer CaP 47 Reports Preclinical Data 47 Naive Patients 47 placebo controlled clinical 47 bortezomib 47 Association EHA 47 Valortim R 47 precursor acute lymphoblastic 47 Endocrine Society ENDO 47 Treatment Naive 47 ELACYT 47 www.nejm.org 47 seliciclib 47 Monoclonal Antibodies 47 Allogeneic 47 Hagop M. 47 ritonavir boosted 47 Melphalan 47 Overactive Bladder OAB 47 antibody blinatumomab MT#/MEDI-# 47 HCV protease 47 BiTE R 47 Bezielle 47 Cloretazine R 47 mapatumumab 47 Radiofrequency Ablation 47 CYT# 47 Erlotinib 47 hematological parameters 47 randomized controlled Phase